To determine whether the locus-specific epigenomic modifications are necessary and sufficient to transform tumor progression in vitro and in vivo, the metastatic PC3 cells expressing CRMP4-TAL-Tet1c and the non-metastatic 22Rv1 cells expressing CRMP4-TAL-3Ac were examined for tissue invasive and cell migratory activities. The gene discussed is DPYSL3; the disease is neoplasm.